期刊文献+

二肽基肽酶抑制剂联合参芪降糖颗粒治疗2型糖尿病患者临床效果观察 被引量:2

Clinical Observation of Dipeptidyl Peptidase-4 Inhibitors Combined with Shenqi Jiangtang Granules in the Treatment of Type 2 Diabetes
下载PDF
导出
摘要 目的:观察并初步研究二肽基肽酶抑制剂联合参芪降糖颗粒治疗2型糖尿病的临床效果。方法:将106例入院的2型糖尿病患者随机分为两组,各53例。对照组采用参芪降糖颗粒治疗,治疗组采用西格列汀和参芪降糖颗粒治疗,对比分析两组患者的临床疗效。结果:术后治疗组总有效率为92.45%,显著高于对照组75.47%(P<0.05);与治疗前相比,治疗后两组患者的空腹血糖、餐后2 h血糖和糖化血红蛋白均有所改善,差异显著(P<0.05);治疗组各指标改善程度均优于对照组,差异有统计学意义(P<0.05);治疗期间,治疗组低血糖发生率(1.9%)低于对照组(9.4%),差异有统计学意义(P<0.05)。结论:二肽基肽酶抑制剂联合参芪降糖颗粒治疗2型糖尿病可明显改善患者的治疗效果,减少患者并发症的发生,在临床实践中值得广泛参考。 Objective:To investigate the clinical effects of dipeptidyl peptidase-4 inhibitors combined with Shenqi Jiangtang granules in treating type 2 diabetes.Methods:A total of 106 hospitalized patients with type 2 diabetes were randomly divided into two groups,53 for each.The control group with shenqi jiangtang granules only,and the treatment group was treated with dipeptidyl peptidase-4 inhibitors combined with Shenqi Jiangtang granules.The clinical efficacy of the two groups was compared and analyzed.Results:The total effective rate of the postoperative treatment group was 92.45%,significantly higher than that of the control group(P<0.05);Compared with before treatment,fasting blood glucose,postprandial blood glucose and glycosylated hemoglobin were improved in the two groups after treatment,with significant difference(P<0.05).The improvement degree of all indicators in the treatment group was better than that in the control group,with statistically significant difference(P<0.05).During the treatment period,the incidence of hypoglycemia in the treatment group(1.9%)was lower than that in the control group(9.4%),and the difference was statistically significant(P<0.05).Conclusion:Dipeptidyl peptidase-4 inhibitors combined with Shenqi Jiangtang granules had significant effect in treating type 2 diabetes,which can obviously improve the treatment effect of patients,reduce the occurrence of patient complications,it is worthy of extensive reference in clinical practice.
作者 程晓郑 Cheng Xiaozheng(Department of Internal Medicine,Puyang County No.2 People's Hospital,Henan Province,Puyang 457100)
出处 《数理医药学杂志》 2020年第2期279-280,共2页 Journal of Mathematical Medicine
关键词 二肽基肽酶抑制剂 参芪降糖颗粒 2型糖尿病 临床效果 dipeptidyl peptidase-4 inhibitor Shenqi jiangtang granules type 2 diabetes mellitus clinical effect
  • 相关文献

参考文献5

二级参考文献84

  • 1李霞,周智广,亓海英,陈小燕,黄干.用空腹C肽代替胰岛素改良Homa公式评价胰岛素抵抗和胰岛β细胞功能[J].中南大学学报(医学版),2004,29(4):419-423. 被引量:209
  • 2Engel M,Hoffmann T,Wagner L,et al.The crystal structure of dipeptidyl peptidase Ⅳ (CD26) reveals its functional regulation and enzymatic mechanism.Proc Natl Acad Sci U S A,2003,100(9):5063-5068.
  • 3Ferreira L,Teixeira-de-Lemos E,Pinto F,et al.Effects of sitagliptin treatment on dysmetabolism,inflammation,and oxidative stress in an animal model of type 2 diabetes (ZDF Rat).Mediators Inflamm,2010:592760.
  • 4Vahl TP,Tauchi M,Durler TS,et al.Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.Endocrinology,2007,148(10):4965-4973.
  • 5Raz I,Hanefeld M,Xu L,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.Diabetologia,2006,49 (11):2564-2571.
  • 6Rhee E,Lee WY,Min KW,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.Diabetes Obes Metab,2013,15(6):523-530.
  • 7Mistry GC,Maes AL,Lasseter KC,et al.Effect of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on blood pressure in nondiabetic patients with mild to moderate hypertension.J Clin Pharmacol,2008,48 (5):592-598.
  • 8Bergman A,Ebel D,Liu F,et al.Absolute bioavailability of sitagliptin,an oral dipeptidyl peptidase-4 inhibitor,in healthy volunteers.Biopharm Drug Dispos,2007,28 (6):315-322.
  • 9Nauck MA,Meininger G,Sheng D,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,sitagliptin,compared with the sulfhonylurea,glipizide,in patients with type 2 diabetes inadequately controlled on metformin alone:a randomized double-blind,non-inferiority trial.Diabetes Obes Metab,2007,9(2):194-205.
  • 10Lenski M,Kazakov A,Marx N,et al.Effects of DPP-4 inhibition on cardiac metabolism and function in mice.J Mol Cell Cardiol,2011,51(6):906-918.

共引文献39

同被引文献25

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部